Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Smith & Nephew (SNN) Receivables (2015 - 2025)

Smith & Nephew (SNN) posted Receivables of $1.6 billion for Q4 2025, up 28.5% on a QoQ basis from $1.2 billion in Q4 2024, and up 28.5% year-over-year from $1.2 billion in Q4 2024.

Smith & Nephew (SNN) has 11 years of Receivables data on file, last reported at $1.6 billion in Q4 2025.

  • In Q4 2025, Receivables rose 28.5% year-over-year to $1.6 billion; the TTM figure through Dec 2025 stood at $1.6 billion (up 28.5% YoY), while the FY2025 annual figure was $1.6 billion, up 28.5% from the prior year.
  • Receivables grew to $1.6 billion in Q4 2025, from $1.2 billion in the prior quarter.
  • Across five years, Receivables topped out at $1.6 billion in Q4 2025 and bottomed at $1.1 billion in Q4 2021.
  • A 5-year average of $1.3 billion and a median of $1.4 billion in 2022 frame the typical range for Receivables.
  • Annual changes were most pronounced in 2022 — Receivables advanced 29.27% — and 2024, when it declined 16.18%.
  • Year by year, Receivables stood at $1.1 billion in 2021, then climbed by 29.27% to $1.4 billion in 2022, then increased by 4.5% to $1.4 billion in 2023, then dropped by 16.18% to $1.2 billion in 2024, then gained by 28.5% to $1.6 billion in 2025.
  • The last three Receivables figures came in at $1.6 billion (Q4 2025), $1.2 billion (Q4 2024), and $1.4 billion (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 8.21 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 3.57 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 6.36 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 3.15 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 973.00 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 3.82 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 1.11 Bn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 4.50 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 1.09 Bn
10 Smith & Nephew 5.16 Bn 4.58 Bn - 1.55 Bn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 1.55 Bn
Dec 31, 2024 1.21 Bn
Dec 31, 2023 1.42 Bn
Dec 31, 2022 1.38 Bn
Dec 31, 2021 1.28 Bn
Dec 31, 2020 1.12 Bn
Dec 31, 2019 1.45 Bn
Dec 31, 2018 1.21 Bn
Dec 31, 2017 1.35 Bn
Dec 31, 2016 1.26 Bn
Dec 31, 2015 1.22 Bn